JP2018520182A - 乳房障害を処置するための経乳頭方法及び組成物 - Google Patents

乳房障害を処置するための経乳頭方法及び組成物 Download PDF

Info

Publication number
JP2018520182A
JP2018520182A JP2018501348A JP2018501348A JP2018520182A JP 2018520182 A JP2018520182 A JP 2018520182A JP 2018501348 A JP2018501348 A JP 2018501348A JP 2018501348 A JP2018501348 A JP 2018501348A JP 2018520182 A JP2018520182 A JP 2018520182A
Authority
JP
Japan
Prior art keywords
composition
breast
cancer
vitamin
nipple
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018501348A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018520182A5 (cg-RX-API-DMAC7.html
Inventor
シー. クェイ,スティーヴン
シー. クェイ,スティーヴン
Original Assignee
アトッサ ジェネティックス インク.
アトッサ ジェネティックス インク.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アトッサ ジェネティックス インク., アトッサ ジェネティックス インク. filed Critical アトッサ ジェネティックス インク.
Publication of JP2018520182A publication Critical patent/JP2018520182A/ja
Publication of JP2018520182A5 publication Critical patent/JP2018520182A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0041—Mammary glands, e.g. breasts, udder; Intramammary administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrane Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2018501348A 2015-07-14 2016-07-14 乳房障害を処置するための経乳頭方法及び組成物 Pending JP2018520182A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562192505P 2015-07-14 2015-07-14
US62/192,505 2015-07-14
PCT/US2016/042202 WO2017011623A1 (en) 2015-07-14 2016-07-14 Transpapillary methods and compositions for treating breast disorders

Publications (2)

Publication Number Publication Date
JP2018520182A true JP2018520182A (ja) 2018-07-26
JP2018520182A5 JP2018520182A5 (cg-RX-API-DMAC7.html) 2019-08-29

Family

ID=57757662

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018501348A Pending JP2018520182A (ja) 2015-07-14 2016-07-14 乳房障害を処置するための経乳頭方法及び組成物

Country Status (7)

Country Link
US (1) US20180200206A1 (cg-RX-API-DMAC7.html)
EP (1) EP3322406A4 (cg-RX-API-DMAC7.html)
JP (1) JP2018520182A (cg-RX-API-DMAC7.html)
CN (1) CN108024959A (cg-RX-API-DMAC7.html)
AU (1) AU2016294526A1 (cg-RX-API-DMAC7.html)
CA (1) CA2992282A1 (cg-RX-API-DMAC7.html)
WO (1) WO2017011623A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
EP3283061A4 (en) * 2015-04-14 2019-04-17 Atossa Genetics Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF BREAST DISEASES AND ORGANISM-RELATED ILLNESSES
EP3679061A4 (en) * 2017-09-06 2021-06-09 University of Cincinnati METHOD OF PREDICTING BREAST LESIONS IN EARLY STAGE
EP3681491A4 (en) 2017-09-11 2021-06-30 Atossa Therapeutics, Inc. PROCESS FOR MANUFACTURING AND USE OF ENDOXIFES
CN110221068B (zh) * 2018-03-02 2020-09-18 中国医学科学院基础医学研究所 检测Kyn含量的试剂的应用
WO2021003433A1 (en) 2019-07-03 2021-01-07 Atossa Therapeutics, Inc. Sustained release compositions of endoxifen

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040030248A1 (en) * 2002-03-19 2004-02-12 Cytyc Health Corporation Intraductal management of breast lesions involving therapeutic or diagnostic agents
US20100112041A1 (en) * 2006-11-21 2010-05-06 Jina Pharmaceuticals, Inc. Endoxifen Compositions And Methods
US20140088059A1 (en) * 2012-07-13 2014-03-27 South Dakota State University Compositions and Methods for Localized Drug Delivery through Mammary Papillae

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6881548B2 (en) * 1997-05-23 2005-04-19 A&G Pharmaceutical, Inc. Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy
US6638727B1 (en) * 1999-01-26 2003-10-28 Cytyc Health Corporation Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
US6398765B1 (en) * 1999-03-01 2002-06-04 Pro Duct Health, Inc. Apparatus, methods and kits for simultaneous delivery of a substance to multiple breast milk ducts
US20020117169A1 (en) * 2001-02-27 2002-08-29 Kurz Daniel R. Cover and applicator for a portion of a mammalian body
JP2004530659A (ja) * 2001-02-28 2004-10-07 ジャイルズ,ブライアン,シー. 抗腫瘍および抗転移作用のための方法および処方
US9808471B2 (en) * 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
KR100419298B1 (ko) * 2003-07-28 2004-02-18 조규학 부착형 브래지어 및 그 제조방법
US7229420B2 (en) * 2003-12-23 2007-06-12 Cytyc Corporation Medical instrument for accessing a breast duct for performing a medical procedure
US20050142315A1 (en) * 2003-12-24 2005-06-30 Desimone Joseph M. Liquid perfluoropolymers and medical applications incorporating same
IL177006A0 (en) * 2005-08-02 2006-12-10 Veridex Llc Predicting bone relapse of breast cancer
WO2007067773A2 (en) * 2005-12-09 2007-06-14 Mayo Foundation For Medical Education And Research Assessing outcomes for breast cancer patients by determining cyp2d6 genotype
ES2539042T3 (es) * 2006-06-02 2015-06-25 Glaxosmithkline Biologicals S.A. Procedimiento de identificación de si un paciente será respondedor o no a inmunoterapia
CA2673870A1 (en) * 2006-12-27 2008-07-10 Emory University Compositions and methods for the treatment of infections and tumors
WO2009105640A1 (en) * 2008-02-22 2009-08-27 Virginia Commonwealth University Signatures associated with rejection or recurrence of cancer
WO2010008427A1 (en) * 2008-04-11 2010-01-21 Ludwig Institute For Cancer Research Ltd. Tryptophan catabolism in cancer treatment and diagnosis
WO2009129352A2 (en) * 2008-04-15 2009-10-22 Windy Hill Medical Device and method for accessing and treating ducts of mammary glands
WO2010009335A1 (en) * 2008-07-17 2010-01-21 Micell Technologies, Inc. Drug delivery medical device
ES2624557T3 (es) * 2008-12-11 2017-07-14 Besins Healthcare Luxembourg Sarl Composiciones farmacéuticas transdérmicas que comprenden un SERM
WO2011072244A1 (en) * 2009-12-10 2011-06-16 Mount Sinai School Of Medicine Of New York University Method of treatment of breast cancer with tamoxifen
EP2425833A1 (de) * 2010-09-03 2012-03-07 Fresenius Kabi Deutschland GmbH Die intravenöse Applikation von Fischöl/DHA +EPA vor bzw. mit Beginn der Chemotherapie
US20130045179A1 (en) * 2011-08-15 2013-02-21 Mihai Ciustea Combination therapy and methods for treatment and prevention of hyperproliferative diseases
US9517183B2 (en) * 2012-01-30 2016-12-13 Patrick B. Ward Nipple abrasion protector
WO2013134230A1 (en) * 2012-03-05 2013-09-12 Xavier University Boron-based 4-hydroxytamoxifen and endoxifen prodrugs as treatment for breast cancer
EP3092027A4 (en) * 2014-01-10 2017-09-06 Atossa Genetics Inc. Transpapillary methods and compositions for diagnosing and treating breast conditions
EP3283061A4 (en) * 2015-04-14 2019-04-17 Atossa Genetics Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF BREAST DISEASES AND ORGANISM-RELATED ILLNESSES

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040030248A1 (en) * 2002-03-19 2004-02-12 Cytyc Health Corporation Intraductal management of breast lesions involving therapeutic or diagnostic agents
US20100112041A1 (en) * 2006-11-21 2010-05-06 Jina Pharmaceuticals, Inc. Endoxifen Compositions And Methods
US20140088059A1 (en) * 2012-07-13 2014-03-27 South Dakota State University Compositions and Methods for Localized Drug Delivery through Mammary Papillae

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 387, JPN6020017335, 2010, pages 161 - 166, ISSN: 0004521862 *
PLOS ONE, vol. 9(12), JPN6020017334, 2014, pages 115712, ISSN: 0004521861 *

Also Published As

Publication number Publication date
AU2016294526A1 (en) 2018-02-08
EP3322406A1 (en) 2018-05-23
WO2017011623A1 (en) 2017-01-19
CN108024959A (zh) 2018-05-11
CA2992282A1 (en) 2017-01-19
US20180200206A1 (en) 2018-07-19
EP3322406A4 (en) 2019-06-12

Similar Documents

Publication Publication Date Title
Šarenac et al. Cervical cancer, different treatments and importance of bile acids as therapeutic agents in this disease
Robertson et al. Inflammatory breast cancer: the disease, the biology, the treatment
CN108024959A (zh) 用于治疗乳腺病症的经乳头方法和组合物
Peart Directed Reading. Breast Intervention and Breast Cancer Treatment Options.
ES2991315T3 (es) Métodos y composiciones relacionados con el antagonismo del receptor de glucocorticoides y con el cáncer de próstata
Chaudary et al. Plerixafor improves primary tumor response and reduces metastases in cervical cancer treated with radio-chemotherapy
Silva et al. Breast cancer: a practical guide
Tsang et al. Radiation therapy for localized low‐grade non‐Hodgkin's lymphomas
Kataja et al. Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up
Dixon et al. Lessons from the use of aromatase inhibitors in the neoadjuvant setting.
JP2017002060A (ja) Diapeutic(登録商標)剤としてのリン脂質類似体、及びその方法
AU2003259578A1 (en) Methods and Devices for Delivery of Agents to Breast Milk Ducts
Park-Simon et al. Arbeitsgemeinschaft Gynäkologische Onkologie recommendations for the diagnosis and treatment of patients with early breast cancer: update 2023
JP2026016396A (ja) 乳がんの治療のための併用療法
US20160375234A1 (en) Transpapillary methods and compositions for diagnosing and treating breast conditions
Bosma et al. Evaluation of early response to preoperative accelerated partial breast irradiation (PAPBI) by histopathology, magnetic resonance imaging, and 18F-fluorodexoyglucose positron emission tomography/computed tomography (FDG PET/CT)
Lan et al. Beyond boundaries: unraveling innovative approaches to combat bone-metastatic cancers
Thorat et al. Nanomedicine: next generation modality of breast cancer therapeutics
TW201600086A (zh) 用於治療三陰性乳癌之維利帕尼(veliparib)與卡鉑之組合
AlKindi A rare case of inflammatory myofibroblastic tumor of the mandible mimicking a malignant tumor
HK1255302A1 (en) Transpapillary methods and compositions for treating breast disorders
Lee et al. In vitro delivery of anti-breast cancer agents directly via the mammary papilla (nipple)
Phillips et al. Current management of breast cancer.
Sharma et al. Recent development in treatment strategies for breast cancer: With special reference to immunotherapy
Dietl et al. FDG-PET in radiotherapy treatment planning of advanced head and neck cancer—a prospective clinical analysis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190712

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190712

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200601

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200828

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210204

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210607